PDL BioPharma Company Profile (NASDAQ:PDLI)

About PDL BioPharma (NASDAQ:PDLI)

PDL BioPharma logoPDL BioPharma, Inc. seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company's segments include income generating assets and product sales. The income generating assets segment consists of royalties from issued patents in the United States and elsewhere, covering the humanization of antibodies, which it refers to as the Queen et al. patents; notes and other long-term receivables, royalty rights-at fair value and equity investments. The Company's product sales segment consists of revenue derived from Tekturna, Tekturna HCT, Rasilez and Rasilez HCT (collectively, the Noden Products or Tekturna) sales. It is focused on the acquisition of additional products. As of December 31, 2016, it had a total of five notes receivable transactions outstanding and one note/royalty (hybrid) receivable transaction outstanding.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:PDLI
  • CUSIP: 69329Y10
  • Web: www.pdl.com
Capitalization:
  • Market Cap: $384.75 million
  • Outstanding Shares: 160,984,000
Average Prices:
  • 50 Day Moving Avg: $2.22
  • 200 Day Moving Avg: $2.29
  • 52 Week Range: $1.93 - $3.77
P/E:
  • Trailing P/E Ratio: 26.26
  • Foreward P/E Ratio: 14.06
  • P/E Growth: 0.64
Sales & Book Value:
  • Annual Revenue: $103.28 million
  • Price / Sales: 3.73
  • Book Value: $4.65 per share
  • Price / Book: 0.51
Profitability:
  • EBIDTA: $45.51 million
  • Net Margins: 49.04%
  • Return on Equity: 29.87%
  • Return on Assets: 20.18%
Debt:
  • Debt-to-Equity Ratio: 0.31%
  • Current Ratio: 2.92%
  • Quick Ratio: 2.91%
Misc:
  • Average Volume: 1.89 million shs.
  • Beta: 0.52
  • Short Ratio: 7.28
 

Frequently Asked Questions for PDL BioPharma (NASDAQ:PDLI)

What is PDL BioPharma's stock symbol?

PDL BioPharma trades on the NASDAQ under the ticker symbol "PDLI."

How will PDL BioPharma's stock buyback program work?

PDL BioPharma announced that its board has approved a share buyback plan on Saturday, April 8th 2017, which allows the company to repurchase $30,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to repurchase up to 8.6% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company's board of directors believes its shares are undervalued.

How were PDL BioPharma's earnings last quarter?

PDL BioPharma Inc (NASDAQ:PDLI) released its earnings results on Wednesday, May, 3rd. The company reported $0.08 EPS for the quarter, topping the Zacks' consensus estimate of $0.05 by $0.03. The company had revenue of $45.44 million for the quarter. PDL BioPharma had a net margin of 49.04% and a return on equity of 29.87%. View PDL BioPharma's Earnings History.

When will PDL BioPharma make its next earnings announcement?

PDL BioPharma is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for PDL BioPharma.

Where is PDL BioPharma's stock going? Where will PDL BioPharma's stock price be in 2017?

2 analysts have issued 12 month price targets for PDL BioPharma's shares. Their forecasts range from $3.50 to $4.00. On average, they expect PDL BioPharma's share price to reach $3.75 in the next twelve months. View Analyst Ratings for PDL BioPharma.

What are analysts saying about PDL BioPharma stock?

Here are some recent quotes from research analysts about PDL BioPharma stock:

  • 1. According to Zacks Investment Research, "PDL BioPharma reported better than expected earnings in the first quarter of 2017 whereas revenue significantly decreased year over year. The company is focused on acquiring and managing income-generating assets. PDL BioPharma has royalty agreements with several companies, whereby it has royalty rights on product sales. We are positive on the company’s recent strategic shift, whereby it is making equity investments in product-focused companies. However, the company’s dependence on revenues from royalties is not a risk-free strategy. Moreover, the company’s top line declined materially after it stopped receiving payments from certain Queen et al. patent license. The decrease in royalties from PDL's Queen et al. patents is due to the expiration of the patent license agreement with Genentech. PDL BioPharma’s shares have underperformed the Medical-Biomedical/Genetics industry in the past one year." (5/15/2017)
  • 2. Cowen and Company analysts commented, "PDL reported an in-line Q1 with both total revenue ($45MM vs $43MM) and EPS." (5/3/2017)

Who are some of PDL BioPharma's key competitors?

Who owns PDL BioPharma stock?

PDL BioPharma's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.57%), Renaissance Technologies LLC (7.27%), Dimensional Fund Advisors LP (3.43%), Acadian Asset Management LLC (2.91%), Mackenzie Financial Corp (2.91%) and AQR Capital Management LLC (2.82%). Company insiders that own PDL BioPharma stock include Peter S Garcia and Steffen Pietzke. View Institutional Ownership Trends for PDL BioPharma.

Who sold PDL BioPharma stock? Who is selling PDL BioPharma stock?

PDL BioPharma's stock was sold by a variety of institutional investors in the last quarter, including UBS Asset Management Americas Inc., Renaissance Technologies LLC, Goldman Sachs Group Inc., Acadian Asset Management LLC, American International Group Inc., Geode Capital Management LLC, Legal & General Group Plc and ClariVest Asset Management LLC. View Insider Buying and Selling for PDL BioPharma.

Who bought PDL BioPharma stock? Who is buying PDL BioPharma stock?

PDL BioPharma's stock was acquired by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Seizert Capital Partners LLC, Thrivent Financial For Lutherans, Vanguard Group Inc., AQR Capital Management LLC, Nomura Holdings Inc., UBS Group AG and Bank of Montreal Can. Company insiders that have bought PDL BioPharma stock in the last two years include Peter S Garcia and Steffen Pietzke. View Insider Buying and Selling for PDL BioPharma.

How do I buy PDL BioPharma stock?

Shares of PDL BioPharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of PDL BioPharma stock cost?

One share of PDL BioPharma stock can currently be purchased for approximately $2.39.

Analyst Ratings

Consensus Ratings for PDL BioPharma (NASDAQ:PDLI) (?)
Ratings Breakdown: 1 Hold Rating, 1 Buy Rating
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $3.75 (56.90% upside)

Analysts' Ratings History for PDL BioPharma (NASDAQ:PDLI)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/3/2017Cowen and CompanyReiterated RatingHoldHighView Rating Details
12/22/2016Piper Jaffray CompaniesInitiated CoverageOverweight$4.00N/AView Rating Details
2/23/2016Royal Bank of CanadaLower Price TargetSector Perform$5.00 -> $4.00N/AView Rating Details
(Data available from 5/27/2015 forward)

Earnings

Earnings History for PDL BioPharma (NASDAQ:PDLI)
Earnings by Quarter for PDL BioPharma (NASDAQ:PDLI)
Earnings History by Quarter for PDL BioPharma (NASDAQ:PDLI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2017        
5/3/2017Q1 2017$0.05$0.08$45.44 millionViewListenView Earnings Details
11/3/2016Q316$0.08$0.08$50.69 million$53.60 millionViewN/AView Earnings Details
8/4/2016Q216$0.08$0.09$33.46 million$21.00 millionViewN/AView Earnings Details
5/4/2016Q116$0.50$0.52$142.05 million$103.10 millionViewN/AView Earnings Details
2/22/2016Q415$0.54$0.61$149.20 million$178.10 millionViewListenView Earnings Details
11/4/2015Q315$0.61$0.42$164.80 million$124.60 millionViewN/AView Earnings Details
8/5/2015Q215$0.52$0.47$137.75 million$138.10 millionViewN/AView Earnings Details
5/6/2015Q115$0.52$0.50$140.80 million$149.71 millionViewN/AView Earnings Details
2/23/2015Q414$0.57$0.32$158.15 million$117.10 millionViewListenView Earnings Details
11/10/2014Q314$0.56$0.61$165.10 million$164.60 millionViewN/AView Earnings Details
8/18/2014Q214$0.46$0.52$134.07 million$162.80 millionViewListenView Earnings Details
5/12/2014Q114$0.45$0.44$130.93 million$139.70 millionViewN/AView Earnings Details
3/3/2014Q413$0.43$0.39$115.22 million$110.10 millionViewN/AView Earnings Details
11/6/2013Q313$0.37$0.36$97.09 million$97.30 millionViewN/AView Earnings Details
8/8/2013Q2 2013$0.54$0.62$138.20 million$143.60 millionViewN/AView Earnings Details
5/9/2013Q1 2013$0.35$0.36$91.69 million$91.80 millionViewN/AView Earnings Details
3/1/2013Q4 2012$0.31$0.34$86.08 million$86.10 millionViewN/AView Earnings Details
11/5/2012Q312$0.33$0.32$85.03 million$85.20 millionViewN/AView Earnings Details
8/2/2012$0.44$0.52ViewN/AView Earnings Details
5/3/2012$0.27$0.29ViewN/AView Earnings Details
2/23/2012$0.28$0.24ViewN/AView Earnings Details
11/9/2011$0.27$0.28ViewN/AView Earnings Details
7/27/2011$0.39$0.39ViewN/AView Earnings Details
4/27/2011$0.24$0.25ViewN/AView Earnings Details
2/28/2011$0.21$0.20ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for PDL BioPharma (NASDAQ:PDLI)
Current Year EPS Consensus Estimate: $0.26 EPS
Next Year EPS Consensus Estimate: $0.17 EPS

Dividends

Current Dividend Information for PDL BioPharma (NASDAQ:PDLI)
Most Recent Dividend:6/13/2016
Annual Dividend:$0.10
Dividend Yield:4.18%
Payout Ratio:9.43% (Trailing 12 Months of Earnings)
38.46% (Based on This Year's Estimates)
58.82% (Based on Next Year's Estimates)
Dividend Payments by Quarter for PDL BioPharma (NASDAQ:PDLI)

Dividend History by Quarter for PDL BioPharma (NASDAQ:PDLI)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/4/2016quarterly$0.056.25%6/2/20166/6/20166/13/2016
2/1/2016quarterly$0.057.27%3/2/20163/4/20163/11/2016
2/2/2015quarterly$0.158.22%6/1/20166/5/20166/12/2016
1/30/2015quarterly$0.158.23%6/3/20156/5/20156/12/2015
1/30/2015quarterly$0.158.23%3/3/20153/5/20153/12/2015
1/30/2015quarterly$0.158.23%12/2/201512/4/201512/11/2015
1/30/2015quarterly$0.158.23%9/2/20159/4/20159/11/2015
1/31/2014quarterly$0.156.59%9/3/20149/5/20149/12/2014
1/31/2014quarterly$0.156.59%3/3/20143/5/20143/12/2014
1/31/2014quarterly$0.156.59%12/3/201412/5/201412/12/2014
1/31/2014quarterly$0.156.59%6/3/20146/5/20146/12/2014
1/31/2013quarterly$0.158.72%12/3/201312/5/201312/12/2013
1/31/2013quarterly$0.158.72%6/3/20136/5/20136/12/2013
1/31/2013quarterly$0.158.72%9/3/20139/5/20139/12/2013
1/30/2013quarterly$0.158.72%3/1/20133/5/20133/12/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for PDL BioPharma (NASDAQ:PDLI)
Insider Ownership Percentage: 1.10%
Institutional Ownership Percentage: 78.88%
Insider Trades by Quarter for PDL BioPharma (NASDAQ:PDLI)
Institutional Ownership by Quarter for PDL BioPharma (NASDAQ:PDLI)
Insider Trades by Quarter for PDL BioPharma (NASDAQ:PDLI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/24/2017Peter S GarciaVPBuy25,000$1.98$49,500.00View SEC Filing  
8/9/2016Peter S GarciaVPBuy10,000$3.00$30,000.00View SEC Filing  
12/15/2015Peter S. GarciaCFOBuy5,000$3.64$18,200.00View SEC Filing  
12/14/2015Peter S. GarciaCFOBuy10,000$3.42$34,200.00View SEC Filing  
12/7/2015Steffen PietzkeCAOBuy20,590$3.64$74,947.60View SEC Filing  
8/14/2015Peter S GarciaCFOBuy20,000$5.83$116,600.00View SEC Filing  
11/26/2014Harold E SelickDirectorBuy6,000$8.08$48,480.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for PDL BioPharma (NASDAQ:PDLI)
Latest Headlines for PDL BioPharma (NASDAQ:PDLI)
Source:
DateHeadline
seekingalpha.com logoPDL BioPharma: Now Is The Time To Buy - Seeking Alpha
seekingalpha.com - May 19 at 11:57 AM
americanbankingnews.com logo Brokerages Expect PDL BioPharma Inc (PDLI) to Announce $0.04 EPS
www.americanbankingnews.com - May 16 at 10:46 AM
americanbankingnews.com logoPDL BioPharma Inc (PDLI) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - May 15 at 12:22 PM
finance.yahoo.com logoLENSAR® And PDL BioPharma Complete Strategic Financial Restructuring Of LENSAR
finance.yahoo.com - May 11 at 8:32 AM
americanbankingnews.com logoPDL BioPharma Inc (PDLI) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS
www.americanbankingnews.com - May 6 at 1:00 AM
streetinsider.com logoLENSAR Receives FDA Clearances for Laser Cataract Platform Integration With OCULUS Pentacam Tomographers (PDLI)
www.streetinsider.com - May 5 at 7:26 PM
finance.yahoo.com logoLENSAR® Receives FDA Clearances for Laser Cataract Platform Integration With OCULUS Pentacam® Tomographers
finance.yahoo.com - May 5 at 7:26 PM
americanbankingnews.com logoPDL BioPharma Inc (PDLI) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 5 at 2:30 PM
finance.yahoo.com logoEdited Transcript of PDLI earnings conference call or presentation 3-May-17 8:30pm GMT
finance.yahoo.com - May 4 at 8:06 AM
americanbankingnews.com logoPDL BioPharma's (PDLI) "Hold" Rating Reiterated at Cowen and Company
www.americanbankingnews.com - May 4 at 12:06 AM
americanbankingnews.com logoCowen and Company Reiterates "Hold" Rating for PDL BioPharma Inc (PDLI)
www.americanbankingnews.com - May 4 at 12:00 AM
rttnews.com logoEARNINGS SUMMARY: Details of PDL BioPharma Inc. Q1 Earnings Report
www.rttnews.com - May 3 at 7:53 PM
finance.yahoo.com logoInvestor Network: PDL BioPharma, Inc. to Host Earnings Call
finance.yahoo.com - May 3 at 7:53 PM
finance.yahoo.com logoPDL BioPharma Announces First Quarter 2017 Financial Results
finance.yahoo.com - May 3 at 7:53 PM
finance.yahoo.com logoPDL BioPharma posts 1Q profit
finance.yahoo.com - May 3 at 7:53 PM
americanbankingnews.com logoPDL BioPharma (PDLI) Receives Media Impact Rating of 0.69
www.americanbankingnews.com - May 2 at 2:50 PM
americanbankingnews.com logoPDL BioPharma (PDLI) Earning Somewhat Positive Media Coverage, Study Shows
www.americanbankingnews.com - April 28 at 1:01 AM
finance.yahoo.com logoPDL BioPharma to Announce First Quarter 2017 Financial Results on May 3, 2017
finance.yahoo.com - April 26 at 6:05 PM
finance.yahoo.com logoPDL BioPharma, Inc. – Value Analysis (NASDAQ:PDLI) : April 26, 2017
finance.yahoo.com - April 26 at 6:05 PM
finance.yahoo.com logoPDL BioPharma, Inc. breached its 50 day moving average in a Bullish Manner : PDLI-US : April 25, 2017
finance.yahoo.com - April 25 at 10:21 AM
finance.yahoo.com logoETFs with exposure to PDL BioPharma, Inc. : April 24, 2017
finance.yahoo.com - April 24 at 5:52 PM
americanbankingnews.com logoPDL BioPharma (PDLI) Receives Coverage Optimism Rating of 0.44
www.americanbankingnews.com - April 24 at 3:22 PM
finance.yahoo.com logoPDL BioPharma Announces Settlement of Keytruda Patent Infringement Lawsuit with Merck
finance.yahoo.com - April 24 at 12:29 PM
finance.yahoo.com logoPDL BioPharma to be paid $19.5 million by Merck to settle Keytruda patent suit
finance.yahoo.com - April 24 at 12:29 PM
americanbankingnews.com logoPDL BioPharma (PDLI) Earning Somewhat Critical News Coverage, Study Shows
www.americanbankingnews.com - April 21 at 9:21 PM
americanbankingnews.com logoPDL BioPharma (PDLI) Board of Directors Announces Stock Repurchase Plan
www.americanbankingnews.com - April 8 at 8:34 AM
finance.yahoo.com logoPDL BioPharma to Hold Annual Meeting of Stockholders on June 9, 2017
finance.yahoo.com - April 7 at 11:49 AM
americanbankingnews.com logoTheStreet Downgrades PDL BioPharma Inc (PDLI) to D+
www.americanbankingnews.com - April 5 at 3:16 PM
finance.yahoo.com logoPDL BioPharma (PDLI) Up 5.9% Since Earnings Report: Can It Continue?
finance.yahoo.com - April 3 at 9:24 AM
americanbankingnews.com logoInsider Buying: PDL BioPharma Inc (PDLI) VP Acquires 25,000 Shares of Stock
www.americanbankingnews.com - March 27 at 11:04 PM
seekingalpha.com logoPDL BioPharma (PDLI) Presents At Oppenheimer 27th Annual Healthcare Conference
seekingalpha.com - March 21 at 6:58 PM
americanbankingnews.com logoZacks: PDL BioPharma Inc (PDLI) Given Average Rating of "" by Brokerages
www.americanbankingnews.com - March 21 at 10:52 AM
finance.yahoo.com logoPDL BioPharma to Present at the Oppenheimer 27th Annual Healthcare Conference
finance.yahoo.com - March 14 at 10:19 AM
biz.yahoo.com logoPDL BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - March 10 at 9:05 AM
seekingalpha.com logoPDL BioPharma (PDLI) Presents At Cowen and Company 37th Annual Health Care Conference
seekingalpha.com - March 8 at 3:52 PM
biz.yahoo.com logoPDL BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - March 8 at 9:10 AM
finance.yahoo.com logoPDL BIOPHARMA, INC. Financials
finance.yahoo.com - March 7 at 7:00 PM
prnewswire.com logoPDL BioPharma to Present at Two Upcoming Investor Conferences - PR Newswire (press release)
www.prnewswire.com - March 4 at 7:12 PM
seekingalpha.com logoPDL BioPharma: 2017 Could Be A Game-Changer - Seeking Alpha
seekingalpha.com - March 4 at 7:12 PM
rttnews.com logoEARNINGS SUMMARY: Details of PDL BioPharma Inc. Q4 Earnings Report
www.rttnews.com - March 3 at 7:11 PM
fool.com logoWhy Tenet Healthcare, Scientific Games, and PDL BioPharma Jumped Today
www.fool.com - March 3 at 7:10 PM
finance.yahoo.com logoEdited Transcript of PDLI earnings conference call or presentation 1-Mar-17 9:30pm GMT
finance.yahoo.com - March 2 at 8:44 AM
finance.yahoo.com logoPDL BioPharma to Present at Two Upcoming Investor Conferences
finance.yahoo.com - March 2 at 8:44 AM
rttnews.com logoPDL BioPharma Board Authorizes $30 Mln Stock Buyback - Quick Facts
www.rttnews.com - March 1 at 7:23 PM
biz.yahoo.com logoPDL BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Fina
us.rd.yahoo.com - March 1 at 7:23 PM
finance.yahoo.com logo6:35 am PDL BioPharma Board authorizes the repurchase of up to $30 mln of the company's common stock through March 2018
finance.yahoo.com - March 1 at 10:31 AM
finance.yahoo.com logoPDL BioPharma Announces $30 Million Share Repurchase Program
finance.yahoo.com - March 1 at 10:31 AM
biz.yahoo.com logoQ4 2016 PDL BioPharma Inc Earnings Release - After Market Close
biz.yahoo.com - March 1 at 10:31 AM
fool.com logoBetter Buy: PDL BioPharma, Inc. vs. Johnson & Johnson
www.fool.com - February 27 at 9:54 AM
finance.yahoo.com logoPDL BioPharma to Announce Fourth Quarter / Year-End 2016 Financial Results on March 1, 2017
finance.yahoo.com - February 22 at 9:14 AM

Social

Chart

PDL BioPharma (PDLI) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by MarketBeat.com Staff